| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5837010 | Journal of Ethnopharmacology | 2013 | 9 Pages |
Abstract
Regarding the difference of the change in total WOMAC score between the two groups (the GCSB-5 group minus the Celecoxibgroup), upper one-sided 97.5% confidence limits did not exceed the pre-specified inferiority clinical margin of 9.
- : GCSB-5 300Â mg, â: GCSB-5 placebo, â: Celecoxib200Â mg, â: Celecoxibplacebo186
- : GCSB-5 300Â mg, â: GCSB-5 placebo, â: Celecoxib200Â mg, â: Celecoxibplacebo186
Keywords
NSAIDSFDAKellgren and LawrenceGCSB-5PGI2LOCFWOMACTxA2ADRMCIDIL-1betaVASCOX-1EfficacyOsteoarthritisstandard deviationITTCOX-2 inhibitorThromboxane A2GEENon-steroidal anti-inflammatory drugsper protocolKneeFood and Drug AdministrationCelecoxibcyclooxygenase-1Western Ontario and McMaster Universities Arthritis IndexAdverse drug reactionAdverse eventsTNF-αintention to treatlast observation carried forwardgeneralized estimating equationvisual analogue scaleCyclooxygenase-2 inhibitorProstaglandin I2
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacology
Authors
Yong-Geun Park, Chul-Won Ha, Chang-Dong Han, Seong-Il Bin, Hee-Chun Kim, Young-Bok Jung, Hong-Chul Lim,